ESMO® 2026 Highlights: Presenter Vignettes – Guillermo De Velasco

Dr. Guillermo De Velasco

Guillermo De Velasco

MD, PhD

Hospital Universitario 12 de Octubre

2074RO
Enfortumab Vedotin (EV) plus Pembrolizumab (P) for Refractory Advanced Melanoma: Primary Results from the PLUG-IN GEM 2301 Trial

2075RO
Phase 1 dose expansion of a tetravalent CD137/PD-L1 bispecific antibody (FS222) in PD-1 inhibitor- resistant melanoma patients.